Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MICARDIS for Insulin Sensitivity in Obesity
NCT00146289Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2005
- Primary completion
- Oct 2005
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in insulin resistance (IR) and obesity comparing MICARDIS with Placebo (2 arms). Primary endpoint: Change in Insulin Sensitivity Index from Baseline to End of Study at 16 weeks. Started Feb 2005; status: completed.
02
Drugs
telmisartan
03
Conditions
insulin resistance (IR)obesity
Beyond the preview
Go deeper on NCT00146289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00146289.